Detection of IL-5 and IL-1 receptor antagonist in bronchoalveolar lavage fluid in acute eosinophilic pneumonia

Journal of Allergy and Clinical Immunology

Volumn 97, Issue 6, 1996, Pages 1366-1374

  Allen, James N ^a,b   Liao, Zhiming ^a   Wewers, Mark D ^a   Altenberger, Elizabeth A ^a   Moore, Sherri A ^a   Allen, Elizabeth D ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Pulmonary and Critical Care Division   (United States)

Author keywords

acute eosinophilic pneumonia; broncholaveolar lavage; eosinophil; GM CSF; IL 1 ; IL 5; IL Ira; TNF

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 5 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBODY DETECTION; ARTICLE; CASE REPORT; EOSINOPHILIA; FEMALE; HUMAN; LEUKOCYTE COUNT; LOEFFLER PNEUMONIA; LUNG ALVEOLUS CELL; LUNG INFILTRATE; LUNG LAVAGE; MALE; PRIORITY JOURNAL; RESPIRATORY FAILURE;

EID: 0029956020     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(96)70206-3     Document Type: Article

References (46)

1. Allen JN, Pacht ER, Gadek JE, Davis WB. Acute cosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 1989;321:569-74.
2. Basten A, Beeson PB. Mechanism of eosinophilia. II. Role of the lymphocyte. J Exp Med 1970;131:1288-305.
3. Spry CJF. Eosinophils: a comprehensive review, and guide to the scientific and medical literature. Oxford: Oxford University Press, 1988.
4. Lu L, Lin Z-H, Shen R-N, Warren DJ, Leemhuis T, Broxmeyer HE. Influence of interleukins 3, 5, and 6 on the growth of eosinophil progenitors in highly enriched human bone marrow in the absence of serum. Exp Hematol 1990;18:1180-6.
5. Butterfield JH, Leiferman KM, Abrams J, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood 1992;79:688-92.
6. Enokihara H, Kajitani H, Nagashima S, et al. Interleukin 5 activity in sera from patients with eosinophilia. Br J Haematol 1990;75:458-62.
7. Sanz MJ, Weg VB, Bolanowski MA, Nourshargh S. IL-1 is a potent inducer of eosinophil accumulation in rat skin. Inhibition of response by a platelet-activating factor antagonist and an anti-human IL-8 antibody. J Immunol 1995;154:1364-73.
8. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3.
9. Wewers MD, Herzyk DJ. Alveolar macrophages differ from blood monocytes in human IL-1β release: quantitation by enzyme-linked immunoassay. J Immunol 1989;143:1635-41.
10. Allen JN, Herzyk DJ, Wewers MD. Colchicine has opposite effects on interleukin-1β and tumor necrosis factor-α production. Am J Physiol Lung Cell Mol Physiol 1991;5:L315-21.
11. Marsh CB, Wewers MD. Cytokine induced interleukin-1 receptor antagonist release in mononuclear phagocyte. Am J Respir Cell Mol Biol 1994;10:521-5.
12. Allen JN, Davis WB, Pacht ER. Diagnostic significance of increased bronchoalveolar lavage fluid eosinophils. Am Rev Respir Dis 1990;142:642-7.
13. Allen JN, Davis WB. State of the art: the eosinophilic lung diseases. Am J Respir Crit Care Med 1994;150:1423-38.
14. Lopez AF, Vadas MA, Woodcock JM, et al. Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils. J Biol Chem 1991;266:24741-7.
15. Migita M, Yamaguchi N, Mita S, et al. Characterization of the human IL-5 receptor on eosinophils. Cell Immunol 1991;133:484-97.
16. Yamaguchi Y, Hayashi Y, Sugama Y, et al. Highly purified interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival: IL-5 as an eosinophil chemotactic factor. J Exp Med 1988;167:1737-42.
17. Kita H, Weiler DA, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ. Release of granule proteins from eosinophils cultured with IL-5. J Immunol 1992;149:629-35.
18. Stern M, Meagher L, Savill J, Haslett C. Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 1992;148:3543-9.
19. van Haelst Pisani C, Kovach JS, Kita H, et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood 1991;78:1538-44.
20. Dickason RR, Huston MM, Huston DP. Enhanced detection of human IL-5 in biological fluids utilizing murine monoclonal antibodies which delineate distinct neutralizing epitopes. Cytokine 1994;6:647-56.
21. Walker C, Bauer W, Braun RK, et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994;150:1038-48.
22. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC Jr. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992;146:109-15.
23. Terada N, Konno A, Tada H, Shirotori K, Ishikawa K, Togawa K. The effect of recombinant human interleukin-5 on eosinophil accumulation and degranulation in human nasal mucosa. J Allergy Clin Immunol 1992;90:160-8.
24. Ohnishi T, Sur S, Collins DS, Fish JE, Gleich GJ, Peters SP. Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge. J Allergy Clin Immunol 1993;92:607-15.
25. Sedgwick JB, Calhoun WJ, Gleich GJ, Kita H, Abrams JS. Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. Am Rev Respir Dis 1991;144:1274-81.
26. Okudaira H, Nogami M, Matsuzaki G, et al. T-cell-dependent accumulation of eosinophils in the lung and its inhibition by monoclonal anti-interleukin-5. Int Arch Allergy Appl Immunol 1991;94:171-3.
27. Gulbenkian AR, Egan RW, Fernandez X, et al. Interleukin-5 modulates eosinophil accumulation in allergic guinea pig. Am Rev Respir Dis 1992;146:263-5.
28. Chand N, Harrisoon JE, Rooney S, et al. Anti-IL-5 monoclonal antibody inhibits allergic late phase bronchial eosinophilia in guinea pigs: a therapeutic approach. Eur J Pharmacol 1992;211:121-3.
29. Mauser PJ, Pitman A, Witt A, et al. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Am Rev Respir Dis 1993;148:1623-7.
30. Van Oosterhout AJ, Ladenius AR, Savelkoul HF, Van Ark I, Delsman KC, Nijkamp FP. Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs. Am Rev Respir Dis 1993;147:548-52.
31. Murali PS, Kumar A, Choi H, Banasal NK, Fink JN, Kurup VP. Aspergillus fumigatus antigen induced eosinophilia in mice is abrogated by anti-IL-5 antibody. J Leukoc Biol 1993;53:264-7.
32. Sawyers CL, Golde DW, Quan S, Nimer SD. Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia. Cancer 1992;69:1342-6.
33. Wierenga EA, Snoek M, de Groot C, et al. Evidence for compartmentalization of functional subsets of CD4+ T lymphocytes in atopic patients. J Immunol 1990;144:4651-6.
34. H2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
35. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986;60:532-8.
36. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-75.
37. Arend WP. Interleukin 1 receptor antagonist: a new member of the interleukin 1 family. J Clin Invest 1991;88:1445-51.
38. Marsh CB, Pope HA, Wewers MD. Fc gamma receptor cross-linking down-regulates IL-1 receptor antagonist and induces IL-1β in mononuclear phagocytes stimulated with endotoxin or Staphylococcus aureus. J Immunol 1994;152:4604-11.
39. Arzt E, Sauer J, Pollmächer T, et al. Glucocorticoids suppress interleukin-1 receptor antagonist synthesis following induction by endotoxin. Endocrinology 1994;134:672-7.
40. Hidi R, Coëffier E, Vargaftig BB. Formation of LTB4 by fMLP-stimulated alveolar macrophages accounts for eosinophil migration in vitro. J Leukoc Biol 1992;51:425-31.
41. Sehmi R, Wardlaw AJ, Cromwell O, Kurihara K, Waltmann P, Kay AB. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 1992;79:2952-9.
42. Villar MTA, Douglass J, Shute J, Church MK, Holgate ST. Interleukin-8 is a chemoatractant for eosinophils primed with interleukin-4. Am Rev Respir Dis 1993;147:A242.
43. Warringa RAJ, Koenderman L, Kok PTM, Kreukniet J, Bruijnzeel PLB. Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3. Blood 1991;77:2694-700.
44. Pasquale CP, Martins MA, Bozza PT, et al. Bradykinin induces eosinophil accumulation in the rat pleural cavity. Int Arch Allergy Appl Immunol 1991;95:244-7.
45. Ebisawa M, Yamada T, Bickel C, Klunk D, Schleimer RP. Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES. J Immunol 1994;153:2153-60.
46. Rand TH, Cruikshank WW, Center DM, Weller PF. CD4-mediated stimulation of human eosinophil: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med 1991;173:1521-8.